16th World CB & CDx Summit Europe

Date: March 30, 2026 - April 1, 2026
Type: In-person
Location: Europe
Areas of Interest: BioPharma, Oncology

We are thrilled to be back at 16^th World Clinical Biomarkers & Companion Diagnostics Summit Europe. Join us and meet our BioPharma team to learn how we help BioPharma companies address challenges throughout the drug development continuum, enhancing efficiency and precision to accelerate the development of better and more effective precision therapeutics.

The SOPHiA GENETICS team is looking forward to seeing you join our Pre-Conference Workshop Day and Plenary Talk.

Pre-Conference Workshop Day on Monday, March 30^th, from 2.30 to 4.30 pm.

“Pioneering Precision Medicine: A Hybrid Future for CDx”

In this workshop, we will explore how a groundbreaking industry collaboration is rethinking current CDx approaches through a hybrid model designed for rapid scalability and access in precision medicine.

This is an invitation-only workshop session. If you are interested in attending, please fill out our Engager Form

Plenary talk on Tuesday, March 31^st, from 12.00 to 12.30 pm.

“Establishing a Scalable Liquid Biopsy Strategy: Foundations of a Global CDx Ecosystem”

Florian Klemm, Technical Product Management Expert, SOPHiA GENETICS

Explore the evolving landscape of NGS-based liquid biopsy adoption and the remaining barriers to equitable access.
Discover how our decentralized approach and advanced analytics enable scalable, robust, and reproducible liquid biopsy testing, supported by real-world evidence from the deployment of MSK-ACCESS® powered with SOPHiA DDM™.
Gain insights into SOPHiA GENETICS’ unique hybrid CDx development and deployment model with diagnostic partners in key markets, streamlining regulatory pathways, accelerating execution, and enabling cost-efficiency at a global scale.

Add to Calendar

Book a Meeting

Instagram

This field is for validation purposes and should be left unchanged.

First Name(Required)

Last Name(Required)

Institution(Required)

Job Title(Required)

Area of Interest(Required)

Email(Required)

Phone(Required)

Country(Required)

Select US State(Required)

Privacy Policy(Required)

By checking this box, I declare that I have read and accepted in full SOPHiA GENETICS privacy policy. The data provided herein is used to process your request. Click here for more information relating to our privacy policy

Marketing Opt-In

I agree to receive information from SOPHiA GENETICS about products, services, events and promotions. I understand I will be able unsubscribe by using the link integrated with the communication at any time.

This field is hidden when viewing the form

Job Title/Industry(Required)

CAPTCHA

Disclaimer notice:
The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expresseda during this presentation are these of the speaker and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview

SOPHiA DDM™ for Genomics

SOPHiA DDM™ for Radiomics

SOPHiA DDM™ for Multimodal

Professional Services